Arvest Investments Inc. Sells 7,046 Shares of Pfizer Inc. (NYSE:PFE)

Arvest Investments Inc. reduced its position in Pfizer Inc. (NYSE:PFE) by 7.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 92,121 shares of the biopharmaceutical company’s stock after selling 7,046 shares during the period. Arvest Investments Inc.’s holdings in Pfizer were worth $2,444,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the 4th quarter worth approximately $32,000. 68.36% of the stock is currently owned by institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

Pfizer stock opened at $26.18 on Thursday. The company’s fifty day moving average price is $26.19 and its 200 day moving average price is $27.08. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a market capitalization of $148.35 billion, a P/E ratio of 18.57, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.